Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen beats Street EPS

AMGN reported second quarter EPS of $0.49, beating the Street consensus estimate by $0.03. Second quarter EPS were up 29% compared to $0.38 for the

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE